Physician profile
Mark V Tetz
NPI 1891779138
$12,109.05
in general payments reported to CMS, 2019-2025
58 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $1,681 · 2021: $1,809 · 2022: $1,745 · 2023: $1,743 · 2024: $2,238 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,303 · Gift: $59.40 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,303.46 |
| Gift | $59.40 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,780.68 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,354.14 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,168.09 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,002.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $713.74 | 2019-2024 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $594.91 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Novo Nordisk INC | $524.32 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $393.78 | 2019-2021 | |
| Pfizer INC. | $359.15 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $331.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $329.62 | 2022-2023 | |
| Axsome Therapeutics, INC. | $303.01 | 2024-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $230.28 | 2021 | |
| Glaxosmithkline, LLC. | $227.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.45 | 2019-2023 | Trintellix |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.